+Compare
PNT
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
707.05M

PNT Price Prediction, POINT Biopharma Global AI Recommendations

Stock market charts, price targets, analyst ratings and a financial calendar

Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for PNT with price predictions
08:00 PM EDT Oct 01, 2023

PNT sees its 50-day moving average cross bearishly below its 200-day moving average

The 50-day moving average for PNT moved below the 200-day moving average on September 29, 2023. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 05, 2023. You may want to consider selling the stock, shorting the stock, or exploring put options on PNT as a result. In of 60 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for PNT turned negative on September 12, 2023. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 29 similar instances when the indicator turned negative. In of the 29 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PNT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for PNT entered a downward trend on October 02, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 17 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PNT advanced for three days, in of 172 cases, the price rose further within the following month. The odds of a continued upward trend are .

PNT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.580) is normal, around the industry mean (22.679). P/E Ratio (6.246) is within average values for comparable stocks, (131.550). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.091). Dividend Yield (0.000) settles around the average of (0.033) among similar stocks. P/S Ratio (2.881) is also within normal values, averaging (308.078).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. PNT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PNT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I. Advisor
published Earnings

PNT is expected to report earnings to rise 25.75% to -30 cents per share on November 10

POINT Biopharma Global PNT Stock Earnings Reports
Q3'23
Est.
$-0.30
Q2'23
Beat
by $0.05
Q1'23
Beat
by $0.16
Q4'22
Beat
by $1.79
Q3'22
Missed
by $0.58
The last earnings report on August 14 showed earnings per share of -23 cents, beating the estimate of -29 cents. With 40.12M shares outstanding, the current market capitalization sits at 707.05M.
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 403.32B. NVO holds the highest valuation in this group at 403.32B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was 18%, and the average quarterly price growth was 23%. BNOX experienced the highest price growth at 337%, while RGMP experienced the biggest fall at -72%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -29%. For the same stocks of the Industry, the average monthly volume growth was 73% and the average quarterly volume growth was 28%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -2 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
4850 West 78th Street
Phone
+1 647 812-2417
Employees
129
Web
https://www.pointbiopharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FPPEX10.60N/A
N/A
MFS Prudent Investor C
BTEFX37.12-0.37
-0.99%
Boston Trust Equity
CORRX29.15-0.43
-1.45%
Columbia Contrarian Core Adv
GMLGX24.57-0.41
-1.66%
GuideMark® Large Cap Core Service
FSCEX15.16-0.26
-1.69%
Fidelity Advisor® Small Cap C

PNT and

Correlation & Price change

A.I.dvisor indicates that over the last year, PNT has been loosely correlated with MOR. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if PNT jumps, then MOR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PNT
1D Price
Change %
PNT100%
+0.30%
MOR - PNT
49%
Loosely correlated
-4.54%
STOK - PNT
44%
Loosely correlated
-6.09%
SLS - PNT
40%
Loosely correlated
-4.27%
IOVA - PNT
39%
Loosely correlated
-2.42%
LUMO - PNT
37%
Loosely correlated
+5.45%
More